Last Saturday, 6-month follow-up data from Imperial College London’s psilocybin vs. escitalopram in major depressive disorder (MDD) study was published (Erritzoe et al., 2024). As a reminder, the original study saw participants randomised to receive either two separate 25 mg doses of psilocybin 3 weeks apart plus daily placebo for 6 weeks (N=30), or two separate 1 mg doses of psilocybin…
